{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:42:16Z","timestamp":1793374936361,"version":"4.5.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This real-world analysis aimed to evaluate the primary endpoint safety profile and the secondary effectiveness and treatment patterns of sodium zirconium cyclosilicate (SZC) for hyperkalemia management in China, addressing the current evidence gap on SZC use in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multi-center, prospective, non-interventional cohort study enrolled patients (aged \u226518 years), including new and ongoing SZC users, from 34-sites. Treatment was categorized into correction-phase (FAS-P1) and maintenance phase (FAS-P2, new and ongoing users). The subgroup analysis was performed in patients undergoing hemodialysis (full analysis set-hemodialysis [FAS-H]). The primary objective included the safety of SZC whereas treatment patterns and effectiveness were the secondary objectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 1,000 enrolled patients, 442, 878, and 474 were included in FAS-P1, FAS-P2, and FAS-H subgroups, respectively. The most frequently used SZC dosage was 5\u00a0g once-daily in FAS-P (42.1%), and FAS-P2 (37.7%). In the FAS-P1 and FAS-P2 groups, 64% and 65.4% of patients reported AEs; 26.9% and 30.8% reported SAEs. The serum potassium (sK\n                      <jats:sup>+<\/jats:sup>\n                      ) was reduced from 5.8 to 5.0\u00a0mmol\/L in FAS-P1. The mean \u201cwith-in\u201d sK\n                      <jats:sup>+<\/jats:sup>\n                      levels over 6-month was 5.1\u00a0mmol\/L in FAS-P2, of which the new-user group were slightly higher vs. ongoing group of FAS-P2 with a mean sK\n                      <jats:sup>+<\/jats:sup>\n                      of 5.2 and 5.0\u00a0mmol\/L, respectively. Furthermore, SZC showed good efficacy in patients with different chronic kidney disease stage subgroups of FAS-P2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      In real-world clinical practice, no new safety issues of SZC were identified. SZC was effective in lowering sK\n                      <jats:sup>+<\/jats:sup>\n                      levels in the correction-phase and remained stable during the maintenance-phase.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1744687","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:46:03Z","timestamp":1778737563000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety, effectiveness and treatment patterns of sodium zirconium cyclosilicate for hyperkalemia management in China: actualize study"],"prefix":"10.3389","volume":"17","author":[{"given":"Nan","family":"Shen","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zeng","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Dalian Medical University","place":["Dalian, Liaoning, China"]},{"name":"Graduate School of Dalian Medical University","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xie","sequence":"additional","affiliation":[{"name":"Dalian Ruikaer Renal Disease Hospital","place":["Dalian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[{"name":"Hefei First People\u2019s Hospital","place":["Hefei, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqiang","family":"Lin","sequence":"additional","affiliation":[{"name":"Wenzhou Integrated Chinese and Western Medicine Hospital","place":["Wenzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Nanyang Central Hospital","place":["Nanyang, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Cai","sequence":"additional","affiliation":[{"name":"Ningbo Traditional Chinese Medicine Hospital","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Cao","sequence":"additional","affiliation":[{"name":"Taixing People\u2019s Hospital","place":["Taizhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Xinghua People\u2019s hospital","place":["Xinghua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Luo","sequence":"additional","affiliation":[{"name":"Hunan Provincial People\u2019s Hospital","place":["Changsha, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wan","sequence":"additional","affiliation":[{"name":"The First Hospital of Nanjing","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henglan","family":"Wu","sequence":"additional","affiliation":[{"name":"The First Hospital of Jiaxing","place":["Jiaxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Ye","sequence":"additional","affiliation":[{"name":"The First People\u2019s Hospital of Kunshan","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Shan","sequence":"additional","affiliation":[{"name":"Chu Hsien-I Memorial Hospital of Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wu","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Hospital of Traditional Chinese Medicine","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Cao","sequence":"additional","affiliation":[{"name":"Handan First Hospital","place":["Handan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lin","sequence":"additional","affiliation":[{"name":"Linfen Central Hospital","place":["Linfen, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Yu","sequence":"additional","affiliation":[{"name":"Shanxi Provincial Hospital of Chinese Medicine","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Wang","sequence":"additional","affiliation":[{"name":"Liaoning Health Industry Group Bensteel General Hospital","place":["Benxi, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdong","family":"He","sequence":"additional","affiliation":[{"name":"Nuclear Industry 416 Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojiang","family":"Tian","sequence":"additional","affiliation":[{"name":"Shiyan People\u2019s Hospital","place":["Shiyan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglei","family":"Wu","sequence":"additional","affiliation":[{"name":"Qidong People\u2019s Hospital Affiliated Qidong Hospital of Nantong University","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Jiang","sequence":"additional","affiliation":[{"name":"Sandun District of Zhejiang Hospital","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xi\u2019an Medical University","place":["Xi\u2019an, Shaanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zuo","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohua","family":"Wang","sequence":"additional","affiliation":[{"name":"Taian City Central Hospital","place":["Tai\u2019an, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changying","family":"Xing","sequence":"additional","affiliation":[{"name":"Jiangsu Province Official Hospital","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Yin","sequence":"additional","affiliation":[{"name":"Changshu No.2 People\u2019s Hospital","place":["Suzhou, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrong","family":"Zhao","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital of Inner Mongolia Medical University","place":["Hohhot, Inner Mongolia, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Ma","sequence":"additional","affiliation":[{"name":"Anshan Central Hospital","place":["Anshan, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Long","sequence":"additional","affiliation":[{"name":"Tianjin People\u2019s Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Teda Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Hu","sequence":"additional","affiliation":[{"name":"Clinical Medical College & Affiliated Hospital of Chengdu University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Shi","sequence":"additional","affiliation":[{"name":"AstraZeneca Investment China Co, Medical Affairs","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Lin","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Dalian Medical University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100222","DOI":"10.1016\/j.clinme.2024.100222","article-title":"Reducing the harm associated in treating hyperkalaemia with insulin and dextrose","volume":"24","author":"Abou Sherif","year":"2024","journal-title":"Clin. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.3390\/jcm13175103","article-title":"Hyperkalemia management with intravenous insulin in patients with reduced kidney function","volume":"13","author":"Alzahrani","year":"2024","journal-title":"J. Clin. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/ki.2014.382","article-title":"A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient","volume":"88","author":"Ash","year":"2015","journal-title":"Kidney Int."},{"key":"B4","first-page":"312","article-title":"Descriptive epidemiological study of hyperkalemia among patients in the emergency department","volume":"30","author":"Bian","year":"2021","journal-title":"Chin. J. Emerg. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"sfaf247","DOI":"10.1093\/ckj\/sfaf247","article-title":"Effect of spironolactone on cardiovascular and renal outcomes in patients with chronic kidney disease","volume":"18","author":"Chen","year":"2025","journal-title":"Clin. Kidney J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1503\/cmaj.100461","article-title":"Management of patients with acute hyperkalemia","volume":"182","author":"Elliott","year":"2010","journal-title":"CMAJ"},{"key":"B9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s41100-023-00512-0","article-title":"Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia","volume":"9","author":"Fujioka","year":"2023","journal-title":"Ren. Replace. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1016\/j.ekir.2021.05.027","article-title":"Mineralocorticoid receptor antagonism in chronic kidney disease","volume":"6","author":"Georgianos","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s40265-018-0991-6","article-title":"Sodium zirconium cyclosilicate: a review in hyperkalaemia","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"iii2","DOI":"10.1093\/ndt\/gfz206","article-title":"Hyperkalemia: pathophysiology, risk factors and consequences","volume":"34","author":"Hunter","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"key":"B13","volume-title":"Lokelma","year":"2018"},{"key":"B14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.clinthera.2023.04.014","article-title":"DIALIZE China: a phase IIIb, randomized, placebo-controlled study to reduce predialysis hyperkalemia with sodium zirconium cyclosilicate in Chinese patients","volume":"45","author":"Ni","year":"2023","journal-title":"Clin. Ther."},{"key":"B15","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.mayocp.2020.06.014","article-title":"Clinical management of hyperkalemia","volume":"96","author":"Palmer","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"B16","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.18553\/jmcp.2017.23.4-a.s2a","article-title":"Clinical and economic impact of hyperkalemia in patients with chronic kidney disease and heart failure","volume":"23","author":"Polson","year":"2017","journal-title":"JMCP"},{"key":"B17","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000504078","article-title":"Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-Month open-label extension of HARMONIZE","volume":"50","author":"Roger","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2024\/5694131","article-title":"The prevalence and risk factors of hyperkalemia in the outpatient setting","volume":"2024","author":"Sevamontree","year":"2024","journal-title":"Int. J. Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e070530","DOI":"10.1136\/bmjopen-2022-070530","article-title":"Evaluation of safety, effectiveness and treatment patterns of sodium zirconium cyclosilicate in management of hyperkalaemia in China: a real-world study protocol","volume":"13","author":"Shen","year":"2023","journal-title":"BMJ Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1398953","DOI":"10.3389\/fphar.2024.1398953","article-title":"Effectiveness, safety, and treatment pattern of sodium zirconium cyclosilicate in Chinese patients with hyperkalemia: interim analysis from a multicenter, prospective, real-world study (actualize study)","volume":"15","author":"Shen","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"100635","DOI":"10.1016\/j.curtheres.2021.100635","article-title":"Patiromer and sodium zirconium cyclosilicate in treatment of hyperkalemia: a systematic review and meta-analysis","volume":"95","author":"Shrestha","year":"2021","journal-title":"Curr. Ther. Res."},{"key":"B22","volume-title":"EU assessment report","year":"2018"},{"key":"B23","doi-asserted-by":"publisher","first-page":"798","DOI":"10.2215\/CJN.12651018","article-title":"Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-Month phase 3 study","volume":"14","author":"Spinowitz","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/ndt\/gfae016","article-title":"Hyperkalaemia-related reduction of RAASi treatment associates with more subsequent inpatient care","volume":"39","author":"Svensson","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"B25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10557-017-6767-5","article-title":"New therapeutic approaches for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors","volume":"32","author":"Tamargo","year":"2018","journal-title":"Cardiovasc Drugs Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1744687\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:46:04Z","timestamp":1778737564000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1744687\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":25,"alternative-id":["10.3389\/fphar.2026.1744687"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1744687","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"1744687"}}